Developer docs
API playgroundTry for free, no card

Search company profiles

LimFlow SA

Full company profile

uuid00026j2

Namestring
LimFlow SA
Legal namestring
LimFlow SA
Websiteurl
limflow.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

LimFlow SA is a venture-backed medical device company founded in 2014 and headquartered in Paris, France, with a U.S. operational headquarters in San Jose, California. The company developed and commercializes the LimFlow System, the first and only FDA-approved (September 2023) and CE-marked (October 2016) device for Transcatheter Arterialization of Deep Veins (TADV) — a minimally-invasive procedure designed to treat patients with chronic limb-threatening ischemia (CLTI) who have exhausted all endovascular and surgical revascularization options and face imminent major amputation. The target patient population in the U.S. alone exceeds 150,000 major amputations per year, with CLTI affecting up to 4 million Americans and disproportionately impacting minority and underserved populations.

The LimFlow System is a purpose-built, fully percutaneous family of products designed to bypass unreconstructable blocked arteries by diverting oxygenated blood through the deep veins back into the ischemic foot. The product family includes the LimFlow ARC arterial catheter (with embedded crossing needle), the V-Ceiver venous catheter (with radiopaque mesh target), the Vector push valvulotome (4Fr over-the-wire device for lysing venous valves while preserving vessel walls), proprietary tapered nitinol crossing stents with electrospun PTFE cover, and extension covered stents to maintain outflow. Clinical evidence supporting the system includes the PROMISE II pivotal trial (105 patients, 76% limb salvage at 12 months, published in the New England Journal of Medicine), PROMISE I, ALPS Registry, and First-in-Human studies, with PROMISE III ongoing.

The business model is direct enterprise sales of capital-procedure hardware to hospitals and ambulatory surgical centers, with procedures reimbursed under CPT code 0620T. Medicare established approximately $45,000 average hospital outpatient payment and approximately $39,620 in ASCs effective January 2026, plus NTAP add-on payments of up to $16,250 for inpatient cases effective October 2024. LimFlow commercialized directly in Europe following CE Mark and built a U.S. field sales organization after FDA approval, with a dedicated HEMA team supporting coding, billing, and prior authorization. As of November 2025, LimFlow was acquired by Inari Medical (now part of Stryker), operating as a subsidiary with LimFlow branding retained and leveraging Inari/Stryker's commercial infrastructure. Total disclosed funding exceeds $73.5 million across Series A (undisclosed, September 2014), Series C (€27M, April 2018, Sofinnova-led), and Series D ($40M, April 2022, Longitude/Soleus-led).

Short descriptiontext

LimFlow SA is a medical device company that develops and commercializes the first FDA-approved system for Transcatheter Arterialization of Deep Veins (TADV) to treat no-option chronic limb-threatening ischemia (CLTI) patients facing major amputation, selling directly to hospitals and ASCs. Acquired by Inari Medical (Stryker) in November 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersIrvine, United States
HQ citystring
Irvine
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
minimally invasive medical devices, peripheral vascular intervention, deep vein arterialization, limb salvage therapy, endovascular stents
Industry1 code
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Peripheral Vascular Medical Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1LimFlow System Device Sales
TypeHardware Sales
Description

The company generates revenue through the sale of its LimFlow System, a family of transcatheter products including the ARC, V-Ceiver, Vector, crossing stents, and extension stents. As of FDA approval in September 2023, the company transitioned from pre-commercial (clinical trial) stage to commercial operations in the U.S. The system was previously commercially available in Europe following CE Mark approval in October 2016.

limflow.com
2Procedure/Reimbursement Revenue
TypeOne Time License
Description

Hospitals and ASCs bill for the LimFlow TADV procedure using CPT code 0620T. Medicare has established specific payment rates: approximately $45,000 average in hospital outpatient departments and $39,620 in ASCs (effective January 2026), plus potential NTAP add-on payments of up to $16,250 for inpatient cases.

capitalfinance.lesechos.fr
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Pricing details3 tiers
1Medicare Hospital Outpatient Payment (2026)
ModelOtherBilling cadencePay-as-you-go
Notes

Average Medicare payment of approximately $45,000 in hospital outpatient department (HOPD) setting, representing a 29% increase from 2025 following reassignment from New Technology APC 1579 to APC 1580.

limflow.com
2Medicare ASC Payment (2026)
ModelOtherBilling cadencePay-as-you-go
Notes

Average Medicare payment of approximately $39,620 in ambulatory surgical center (ASC) setting, representing a 25% increase from 2025. Facility payment not subject to multiple procedure discounting.

limflow.com
3Medicare NTAP Inpatient Add-on Payment
ModelOtherBilling cadencePay-as-you-go
Notes

Incremental payment of up to $16,250 from Medicare for inpatient LimFlow TADV cases in addition to applicable MS-DRG payment, effective October 1, 2024.

limflow.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

LimFlow SA develops, manufactures and commercializes the LimFlow System for Transcatheter Arterialization of Deep Veins (TADV), a fully percutaneous, minimally-invasive family of medical devices used to bypass blocked arteries in the legs of patients with end-stage Chronic Limb-Threatening Ischemia (CLTI) who have no remaining endovascular or surgical revascularization options. The system delivers oxygenated blood back into the foot via the deep veins to prevent major amputation, heal wounds and relieve pain, and is sold to hospitals and ambulatory surgical centers through direct enterprise sales.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 76% limb salvage at 12 months in PROMISE II pivotal trial
+6 more records
Product overview1 text field

LimFlow SA offers the LimFlow System for Transcatheter Arterialization of Deep Veins (TADV), a comprehensive family of fully percutaneous medical devices designed to treat chronic limb-threatening ischemia (CLTI) in patients with no other revascularization options. The system consists of multiple interconnected components: the LimFlow ARC arterial catheter and V-Ceiver venous catheter for artery-to-vein crossing, the Vector valvulotome for lysing venous valves, and proprietary Crossing Stents and Extension Covered Stents to maintain the arterialized flow pathway. Together, these products restore blood flow to the ischemic foot by diverting blood around diseased arteries through the deep veins, potentially avoiding major amputation and promoting wound healing.

Product and service6 records
1LimFlow System for Transcatheter Arterialization of Deep Veins (TADV)
CategoryPeripheral vascular intervention / limb salvage medical device
Description

Minimally-invasive, fully percutaneous medical device system designed to bypass blocked arteries in the leg and deliver oxygenated blood back into the foot via the deep veins, for patients with chronic limb-threatening ischemia (CLTI) who have no remaining endovascular or surgical revascularization options and are at risk of major amputation. Sold to hospitals and ambulatory surgical centers.

2LimFlow ARC Arterial Catheter (2nd Generation)
CategoryPeripheral vascular intervention catheter
Description

Purpose-built arterial catheter that enables optimal visual alignment under fluoroscopy for artery-to-vein crossing during the LimFlow TADV procedure; features an embedded crossing needle with long reach for multiple crossing options in below-the-knee procedures. A sub-component of the LimFlow System sold as part of the integrated TADV platform.

3LimFlow V-Ceiver Venous Catheter (2nd Generation)
CategoryPeripheral vascular intervention catheter
Description

Purpose-built venous catheter with a radiopaque mesh that fills the vein to provide a distinct visual target during artery-to-vein crossing in the LimFlow TADV procedure. Sub-component of the integrated LimFlow System.

4LimFlow Vector Valvulotome
CategoryPeripheral vascular intervention device
Description

Unique 4Fr over-the-wire push valvulotome specifically designed to lyse venous valves by pushing downward from tibial to distal pedal veins, with a cutting basket featuring forward-facing hooks designed to preserve venous walls and avoid vessel trauma. Sub-component of the LimFlow System.

5LimFlow Crossing Stent System
CategoryPeripheral vascular stent
Description

Proprietary tapered nitinol crossing stent with electrospun PTFE cover material designed to create the channel for blood to flow from artery to vein and to optimize sizing for both artery and vein to maximize flow. Sub-component of the LimFlow System.

6LimFlow Extension Covered Stents
CategoryPeripheral vascular stent
Description

Novel electrospun PTFE-covered nitinol extension stents designed to maximize outflow to the foot by keeping valves in the calf open while blocking smaller veins from taking flow back to the heart. Sub-component of the LimFlow System.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

LimFlow is now part of the Inari Medical family (Inari Medical was acquired by Stryker). The company operates as a subsidiary with LimFlow branding maintained. Inari provides commercial infrastructure, health economics support, and organizational resources. Website states 'LimFlow is proud to be part of the Inari Medical family.'

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Boston Scientific's peripheral intervention franchise (Eluvia drug-eluting stent, Ranger balloon, atherectomy, thrombectomy) addresses CLTI and PAD with overlapping patient populations. It is comparable as a large, diversified peripheral vascular incumbent selling to the same vascular specialist channel as LimFlow.

2Avinger
TypeEmerging player
Description

Avinger develops catheter-based lumivascular systems for peripheral artery disease, addressing below-the-knee and femoropopliteal lesions. It overlaps with LimFlow in the peripheral vascular intervention space, though with a smaller commercial footprint and a focus on atherectomy rather than venous arterialization.

TypeDirect peer
Description

Inari Medical develops catheter-based thrombectomy systems for venous thromboembolism and is now LimFlow's parent within Stryker. It is comparable as a venture-built peripheral vascular intervention company with a specialized catheter platform, similar commercial model, and the same hospital and vascular specialist customer base.

TypeBroad incumbent
Description

Medtronic's peripheral vascular and cardiac surgery businesses (including drug-coated balloons, stents, and TAVR heritage of VP Commercial Ops Mike Mathias) serve the same vascular specialist call point as LimFlow. As a broad incumbent, it offers overlapping capabilities that could reduce the no-option CLTI pool.

TypeDirect peer
Description

Silk Road Medical commercializes minimally-invasive devices (TCAR) for vascular disease with a similarly narrow, well-defined clinical indication and reliance on specialist training and reimbursement. It shares LimFlow's profile as a single-platform peripheral vascular company selling capital-light consumables through specialist channels.

TypeDirect peer
Description

Penumbra develops catheter-based mechanical thrombectomy and vascular intervention devices for peripheral and neurovascular applications. It is comparable to LimFlow as a venture-built catheter-based peripheral vascular intervention company selling disposable devices to vascular specialists and hospitals.

7Terumo (Terumo Interventional Systems)
TypeBroad incumbent
Description

Terumo's interventional systems business manufactures peripheral vascular catheters, guidewires, and stent systems used by vascular specialists. It overlaps with LimFlow in the peripheral vascular intervention device category and shares Japanese and European market presence relevant to LimFlow's international expansion plans.

TypeBroad incumbent
Description

Abbott's vascular division offers a broad portfolio of peripheral intervention devices including drug-coated balloons, stents, and atherectomy systems (via CSI acquisition). It serves the same vascular specialists and hospitals as LimFlow and could compete indirectly by keeping more patients within conventional revascularization pathways.

TypeBroad incumbent
Description

Shockwave pioneered intravascular lithotripsy (IVL) for calcified peripheral and coronary lesions, an alternative revascularization approach for CLTI patients. It is comparable to LimFlow as a peripheral vascular intervention company whose technology can compete for the same CLTI patient pool, and is now part of J&J's cardiovascular franchise.

TypeBroad incumbent
Description

Philips' image-guided therapy business sells peripheral vascular imaging, atherectomy, and therapeutic devices to vascular specialists and hospitals. It is comparable to LimFlow as a broad incumbent operating across the peripheral vascular intervention workflow with overlapping hospital customers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LimFlow SA

Peripheral Vascular Medical Deviceslimflow.com

LimFlow SA is a medical device company that develops and commercializes the first FDA-approved system for Transcatheter Arterialization of Deep Veins (TADV) to treat no-option chronic limb-threatening ischemia (CLTI) patients facing major amputation, selling directly to hospitals and ASCs. Acquired by Inari Medical (Stryker) in November 2025.

What LimFlow SA does

LimFlow SA is a venture-backed medical device company founded in 2014 and headquartered in Paris, France, with a U.S. operational headquarters in San Jose, California. The company developed and commercializes the LimFlow System, the first and only FDA-approved (September 2023) and CE-marked (October 2016) device for Transcatheter Arterialization of Deep Veins (TADV) — a minimally-invasive procedure designed to treat patients with chronic limb-threatening ischemia (CLTI) who have exhausted all endovascular and surgical revascularization options and face imminent major amputation. The target patient population in the U.S. alone exceeds 150,000 major amputations per year, with CLTI affecting up to 4 million Americans and disproportionately impacting minority and underserved populations.

The LimFlow System is a purpose-built, fully percutaneous family of products designed to bypass unreconstructable blocked arteries by diverting oxygenated blood through the deep veins back into the ischemic foot. The product family includes the LimFlow ARC arterial catheter (with embedded crossing needle), the V-Ceiver venous catheter (with radiopaque mesh target), the Vector push valvulotome (4Fr over-the-wire device for lysing venous valves while preserving vessel walls), proprietary tapered nitinol crossing stents with electrospun PTFE cover, and extension covered stents to maintain outflow. Clinical evidence supporting the system includes the PROMISE II pivotal trial (105 patients, 76% limb salvage at 12 months, published in the New England Journal of Medicine), PROMISE I, ALPS Registry, and First-in-Human studies, with PROMISE III ongoing.

The business model is direct enterprise sales of capital-procedure hardware to hospitals and ambulatory surgical centers, with procedures reimbursed under CPT code 0620T. Medicare established approximately $45,000 average hospital outpatient payment and approximately $39,620 in ASCs effective January 2026, plus NTAP add-on payments of up to $16,250 for inpatient cases effective October 2024. LimFlow commercialized directly in Europe following CE Mark and built a U.S. field sales organization after FDA approval, with a dedicated HEMA team supporting coding, billing, and prior authorization. As of November 2025, LimFlow was acquired by Inari Medical (now part of Stryker), operating as a subsidiary with LimFlow branding retained and leveraging Inari/Stryker's commercial infrastructure. Total disclosed funding exceeds $73.5 million across Series A (undisclosed, September 2014), Series C (€27M, April 2018, Sofinnova-led), and Series D ($40M, April 2022, Longitude/Soleus-led).

LimFlow SA firmographics

Firmographics
Name
LimFlow SA
Legal name
LimFlow SA
Website
https://limflow.com
Company type
Private
Founded year
2014
Operating status
Acquired
Headcount range
11–50 employees
Short description
LimFlow SA is a medical device company that develops and commercializes the first FDA-approved system for Transcatheter Arterialization of Deep Veins (TADV) to treat no-option chronic limb-threatening ischemia (CLTI) patients facing major amputation, selling directly to hospitals and ASCs. Acquired by Inari Medical (Stryker) in November 2025.
Ownership category
akta.pro rank

LimFlow SA industry classification

Industry
Product category
Peripheral Vascular Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Minimally invasive medical devices
  • Peripheral vascular intervention
  • Deep vein arterialization
  • Limb salvage therapy
  • Endovascular stents

Where LimFlow SA is headquartered

Location

Headquarters

HQ city
Irvine
HQ country
United States
HQ region
North America

Offices2 records

Markets served

LimFlow SA business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. LimFlow System Device Sales: The company generates revenue through the sale of its LimFlow System, a family of transcatheter products including the ARC, V-Ceiver, Vector, crossing stents, and extension stents. As of FDA approval in September 2023, the company transitioned from pre-commercial (clinical trial) stage to commercial operations in the U.S. The system was previously commercially available in Europe following CE Mark approval in October 2016.
  2. Procedure/Reimbursement Revenue: Hospitals and ASCs bill for the LimFlow TADV procedure using CPT code 0620T. Medicare has established specific payment rates: approximately $45,000 average in hospital outpatient departments and $39,620 in ASCs (effective January 2026), plus potential NTAP add-on payments of up to $16,250 for inpatient cases.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goMedicare Hospital Outpatient Payment (2026)
OtherPay-as-you-goMedicare ASC Payment (2026)
OtherPay-as-you-goMedicare NTAP Inpatient Add-on Payment

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

LimFlow SA product offering

Product offering

Core offering

LimFlow SA develops, manufactures and commercializes the LimFlow System for Transcatheter Arterialization of Deep Veins (TADV), a fully percutaneous, minimally-invasive family of medical devices used to bypass blocked arteries in the legs of patients with end-stage Chronic Limb-Threatening Ischemia (CLTI) who have no remaining endovascular or surgical revascularization options. The system delivers oxygenated blood back into the foot via the deep veins to prevent major amputation, heal wounds and relieve pain, and is sold to hospitals and ambulatory surgical centers through direct enterprise sales.

Product overview

LimFlow SA offers the LimFlow System for Transcatheter Arterialization of Deep Veins (TADV), a comprehensive family of fully percutaneous medical devices designed to treat chronic limb-threatening ischemia (CLTI) in patients with no other revascularization options. The system consists of multiple interconnected components: the LimFlow ARC arterial catheter and V-Ceiver venous catheter for artery-to-vein crossing, the Vector valvulotome for lysing venous valves, and proprietary Crossing Stents and Extension Covered Stents to maintain the arterialized flow pathway. Together, these products restore blood flow to the ischemic foot by diverting blood around diseased arteries through the deep veins, potentially avoiding major amputation and promoting wound healing.

Differentiator

Problem solved

Functional benefit

Products and services

  • LimFlow System for Transcatheter Arterialization of Deep Veins (TADV) Minimally-invasive, fully percutaneous medical device system designed to bypass blocked arteries in the leg and deliver oxygenated blood back into the foot via the deep veins, for patients with chronic limb-threatening ischemia (CLTI) who have no remaining endovascular or surgical revascularization options and are at risk of major amputation. Sold to hospitals and ambulatory surgical centers.
  • LimFlow ARC Arterial Catheter (2nd Generation) Purpose-built arterial catheter that enables optimal visual alignment under fluoroscopy for artery-to-vein crossing during the LimFlow TADV procedure; features an embedded crossing needle with long reach for multiple crossing options in below-the-knee procedures. A sub-component of the LimFlow System sold as part of the integrated TADV platform.
  • LimFlow V-Ceiver Venous Catheter (2nd Generation) Purpose-built venous catheter with a radiopaque mesh that fills the vein to provide a distinct visual target during artery-to-vein crossing in the LimFlow TADV procedure. Sub-component of the integrated LimFlow System.
  • LimFlow Vector Valvulotome Unique 4Fr over-the-wire push valvulotome specifically designed to lyse venous valves by pushing downward from tibial to distal pedal veins, with a cutting basket featuring forward-facing hooks designed to preserve venous walls and avoid vessel trauma. Sub-component of the LimFlow System.
  • LimFlow Crossing Stent System Proprietary tapered nitinol crossing stent with electrospun PTFE cover material designed to create the channel for blood to flow from artery to vein and to optimize sizing for both artery and vein to maximize flow. Sub-component of the LimFlow System.
  • LimFlow Extension Covered Stents Novel electrospun PTFE-covered nitinol extension stents designed to maximize outflow to the foot by keeping valves in the calf open while blocking smaller veins from taking flow back to the heart. Sub-component of the LimFlow System.

Quantifiable outcome

  • 76% limb salvage at 12 months in PROMISE II pivotal trial
  • +6 more outcomes

Companies that use LimFlow SA

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles3 records

LimFlow SA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

LimFlow SA partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Inari Medical (now part of Stryker)coreStrategic or Co-development PartnerLimFlow is now part of the Inari Medical family (Inari Medical was acquired by Stryker). The company operates as a subsidiary with LimFlow branding maintained. Inari provides commercial infrastructure, health economics support, and organizational resources. Website states 'LimFlow is proud to be part of the Inari Medical family.'

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

LimFlow SA competitors and assessment

Company assessment

Broad incumbents

  • Boston Scientific: Boston Scientific's peripheral intervention franchise (Eluvia drug-eluting stent, Ranger balloon, atherectomy, thrombectomy) addresses CLTI and PAD with overlapping patient populations. It is comparable as a large, diversified peripheral vascular incumbent selling to the same vascular specialist channel as LimFlow.
  • Medtronic: Medtronic's peripheral vascular and cardiac surgery businesses (including drug-coated balloons, stents, and TAVR heritage of VP Commercial Ops Mike Mathias) serve the same vascular specialist call point as LimFlow. As a broad incumbent, it offers overlapping capabilities that could reduce the no-option CLTI pool.
  • Terumo (Terumo Interventional Systems): Terumo's interventional systems business manufactures peripheral vascular catheters, guidewires, and stent systems used by vascular specialists. It overlaps with LimFlow in the peripheral vascular intervention device category and shares Japanese and European market presence relevant to LimFlow's international expansion plans.
  • Abbott Vascular: Abbott's vascular division offers a broad portfolio of peripheral intervention devices including drug-coated balloons, stents, and atherectomy systems (via CSI acquisition). It serves the same vascular specialists and hospitals as LimFlow and could compete indirectly by keeping more patients within conventional revascularization pathways.
  • Shockwave Medical (Johnson & Johnson): Shockwave pioneered intravascular lithotripsy (IVL) for calcified peripheral and coronary lesions, an alternative revascularization approach for CLTI patients. It is comparable to LimFlow as a peripheral vascular intervention company whose technology can compete for the same CLTI patient pool, and is now part of J&J's cardiovascular franchise.
  • Philips (Image-Guided Therapy / Peripheral Vascular): Philips' image-guided therapy business sells peripheral vascular imaging, atherectomy, and therapeutic devices to vascular specialists and hospitals. It is comparable to LimFlow as a broad incumbent operating across the peripheral vascular intervention workflow with overlapping hospital customers.

Emerging players

  • Avinger: Avinger develops catheter-based lumivascular systems for peripheral artery disease, addressing below-the-knee and femoropopliteal lesions. It overlaps with LimFlow in the peripheral vascular intervention space, though with a smaller commercial footprint and a focus on atherectomy rather than venous arterialization.

Direct peers

  • Inari Medical (Stryker): Inari Medical develops catheter-based thrombectomy systems for venous thromboembolism and is now LimFlow's parent within Stryker. It is comparable as a venture-built peripheral vascular intervention company with a specialized catheter platform, similar commercial model, and the same hospital and vascular specialist customer base.
  • Silk Road Medical: Silk Road Medical commercializes minimally-invasive devices (TCAR) for vascular disease with a similarly narrow, well-defined clinical indication and reliance on specialist training and reimbursement. It shares LimFlow's profile as a single-platform peripheral vascular company selling capital-light consumables through specialist channels.
  • Penumbra: Penumbra develops catheter-based mechanical thrombectomy and vascular intervention devices for peripheral and neurovascular applications. It is comparable to LimFlow as a venture-built catheter-based peripheral vascular intervention company selling disposable devices to vascular specialists and hospitals.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

LimFlow SA social profiles

Digital presence

LimFlow SA compliance and trust

Trust signal

Compliance2 records

LimFlow SA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LimFlow SA leadership team

Management profile

Number of profiles

Profiles7 records

LimFlow SA funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LimFlow SA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LimFlow SA

What does LimFlow SA do?

LimFlow SA develops, manufactures and commercializes the LimFlow System for Transcatheter Arterialization of Deep Veins (TADV), a fully percutaneous, minimally-invasive family of medical devices used to bypass blocked arteries in the legs of patients with end-stage Chronic Limb-Threatening Ischemia (CLTI) who have no remaining endovascular or surgical revascularization options. The system delivers oxygenated blood back into the foot via the deep veins to prevent major amputation, heal wounds and relieve pain, and is sold to hospitals and ambulatory surgical centers through direct enterprise sales.

Is LimFlow SA a public or private company?

LimFlow SA is a private company. It is classified as corporate owned and is currently acquired.

When was LimFlow SA founded?

LimFlow SA was founded in 2014. It employs 11 to 50 people.

Where is LimFlow SA based?

LimFlow SA is headquartered in Irvine, United States, in the North America region.

How does LimFlow SA make money?

Two revenue lines are on record. LimFlow System Device Sales are the primary driver. The others are procedure/Reimbursement Revenue.

Who are LimFlow SA's main competitors?

Broad incumbents on record are Boston Scientific, Medtronic, Terumo (Terumo Interventional Systems), Abbott Vascular, Shockwave Medical (Johnson & Johnson) and Philips (Image-Guided Therapy / Peripheral Vascular). Avinger is listed as an emerging player. Direct peers are Inari Medical (Stryker), Silk Road Medical and Penumbra.

Does LimFlow SA have an API?

No public API is recorded for LimFlow SA.

What industry is LimFlow SA in?

LimFlow SA's product category is Peripheral Vascular Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Tech.euSofinnova Partners closes oversubscribed €82M Sofinnova MD Start IV fundSofinnova Partners closed its fourth medtech fund, Sofinnova MD Start IV, at €82 million. The oversubscribed fund will support six to eight medtech companies over five years, following MD Start III's €63 million fund. The strategy aims to launch ventures from inception through clinical milestones.BenzingaArterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: AnalystNeedham began coverage on Inari Medical Inc, identifying it as a leader in the venous thrombectomy market, projecting a total available market of $5.8 billion for its FlowTriever and ClotTriever products. Inari Medical recently acquired LimFlow SA for $250 million, with the potential for a total transaction value of $415 million, and is considered a compelling acquisition target for major medical technology firms. The company's shares are currently attractively valued, trading at a premium relative to peers in the sector.Mpo-magInari Medical Closes Acquisition of LimFlowInari Medical has completed the acquisition of LimFlow for an upfront consideration of $250 million, with potential additional contingent payments of up to $165 million. This strategic move integrates LimFlow's FDA-approved TADV system into Inari's portfolio to address unmet needs in treating chronic limb-threatening ischemia. The transaction aims to provide new treatment options for approximately 55,000 U.S. patients annually who previously had no alternatives to amputation.GlobeNewswireInari Medical Closes Acquisition of LimFlowInari Medical closed its acquisition of LimFlow S.A., a limb salvage company for chronic limb-threatening ischemia. The deal includes $250 million in upfront cash and up to $165 million in contingent payments tied to commercial and reimbursement milestones, payable between 2025 and 2027.LwLatham & Watkins Advises Inari Medical in Acquisition of LimFlowInari Medical agreed to acquire LimFlow, a limb salvage company, paying $250 million in cash at closing with additional milestone payments. The deal is expected to close in the fourth quarter of 2023, with Latham & Watkins advising Inari.MedTech DiveInari Medical to buy limb-saving device maker LimFlow for up to $415MInari Medical has agreed to acquire LimFlow, a maker of devices for treating chronic limb-threatening ischemia, in a deal valued at up to $415 million. The acquisition adds LimFlow's FDA-approved technology, which bypasses blocked arteries to save limbs from amputation, to Inari’s vascular portfolio. The transaction is expected to close in the fourth quarter of 2023.FierceBiotechBlood-clot buster Inari snatches up limb-saving implant maker LimFlow for $415MInari Medical agreed to acquire LimFlow, a maker of limb-saving implants, in a deal valued at up to $415 million. The acquisition follows LimFlow's recent FDA approval for its transcatheter bypass system, which demonstrated significant success in preventing amputations among patients with chronic limb-threatening ischemia. Inari plans to integrate the technology into its portfolio and expand its dedicated sales force while reporting strong third-quarter financial results.VascularnewsLimFlow announces agreement to be acquired by Inari MedicalInari Medical has entered into a definitive agreement to acquire LimFlow for up to US$415 million, comprising US$250 million in cash and potential milestone payments. The transaction, expected to close in the fourth quarter of 2023, aims to expand patient access to LimFlow's FDA-approved transcatheter arterialisation system for treating chronic limb-threatening ischemia.GlobeNewswireInari Medical Expands Its Patient-Focused Mission with Agreement to Acquire LimFlowInari Medical has entered into a definitive agreement to acquire LimFlow, a private medical device company specializing in treatments for chronic limb-threatening ischemia, for an upfront cash payment of $250 million plus potential milestone payments. The transaction is expected to close in the fourth quarter of 2023 and aims to expand Inari's portfolio with LimFlow's FDA-approved minimally-invasive system for patients with no other treatment options. This acquisition aligns with Inari's strategy to address significant unmet patient needs in the vascular medicine market.PharmafileFDA approves LimFlow system for patients with CLTIThe FDA approved LimFlow's LimFlow System for treating chronic limb-threatening ischemia patients with no other options. The system restores blood flow in deep veins, and the approval follows the PROMISE II trial, where 76% of patients kept their legs and saw wound healing.